Loading
Receptor Mechanisms and Signaling / Hormonal Regulation and Hypertension · Journal article
Receptors · August 11, 2026
Raises a question worth testing. It does not answer one.
This narrative review summarizes the known biology of the prorenin receptor (PRR) and its proposed roles in cardiovascular, metabolic, and renal disease pathogenesis based on mechanistic and associational evidence. It identifies PRR as a potential biomarker and therapeutic target but does not present clinical trial evidence or definitive causal proof of efficacy in any disease.
Narrative review.
PRR binding by renin or prorenin enhances local angiotensin II generation and initiates Ang II-independent intracellular signaling pathways (ERK1/2, PI3K/Akt, TGF-β, NF-κB) PRR serves as an essential accessory component of vacuolar H+-ATPase complex, regulating vesicular acidification, lysosomal function, autophagy, and Wnt/β-catenin signaling ATP6AP2 gene deficiency causes embryonic lethality, demonstrating PRR's indispensable role in embryonic development and tissue homeostasis
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies PRR as a novel therapeutic target across multiple disease domains but does not provide evidence from clinical trials to guide current practice. Clinicians should recognize PRR biology as an emerging research area requiring translation into clinical studies.
This is a narrative review synthesizing mechanistic evidence and observational associations of the prorenin receptor across multiple diseases, without reporting primary clinical trial data or definitive causal evidence.
As stated by the source record.
This review identifies PRR as a novel therapeutic target across multiple disease domains but does not provide evidence from clinical trials to guide current practice. Clinicians should recognize PRR biology as an emerging research area requiring translation into clinical studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The renin–angiotensin–aldosterone system (RAAS) is a fundamental regulator of blood pressure, electrolyte balance, fluid homeostasis, and tissue remodeling. The discovery of the prorenin receptor (PRR), the protein encoded by the ATP6AP2 gene, has substantially expanded the classical RAAS paradigm by demonstrating that prorenin possesses biological activity beyond its proteolytic conversion to renin. Binding of renin or prorenin to PRR enhances local angiotensin II (Ang II) generation while simultaneously initiating Ang II-independent intracellular signaling pathways, including ERK1/2, mitogen-activated protein kinases, PI3K/Akt, transforming growth factor-β, and nuclear factor-κB, thereby promoting inflammation, oxidative stress, fibrosis, cellular proliferation, and extracellular matrix accumulation. Beyond its receptor function, PRR serves as an essential accessory component of the vacuolar H+-ATPase (V-ATPase) complex, regulating vesicular acidification, lysosomal function, autophagy, protein trafficking, cellular metabolism, and Wnt/β-catenin signaling. These diverse functions explain its indispensable role in embryonic development, cell differentiation, and tissue homeostasis, as evidenced by the embryonic lethality associated with ATP6AP2 gene deficiency. PRR is predominantly localized to intracellular organelles, including the endoplasmic reticulum, Golgi apparatus, endosomes, lysosomes, and autophagic vesicles, although membrane-bound and soluble forms also contribute to physiological and pathological processes. Increasing evidence implies dysregulated PRR signaling in the development and progression of hypertension, cardiovascular disease, chronic kidney disease, diabetes, obesity, and other metabolic disorders. This review summarizes current advances in PRR and soluble PRR biology, discusses unresolved mechanistic and translational questions, and evaluates the potential of PRR as a biomarker and therapeutic target for cardiovascular, renal, and metabolic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.